Transcode Therapeutics Inc
RNAZ8.910USD
-1.060-10.63%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
7.43M시가총액
손실P/E TTM
자세한 내용은 Transcode Therapeutics Inc 회사
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. It is defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a biomarker of metastasis. The Company is also developing a portfolio of RNA therapeutic candidates to overcome delivery challenges and unlock access to novel genetic targets. Its preclinical programs include TTX-siPDL1 (siRNA modulator of PD-L1), TTX-RIGA (RNA agonist of RIG-I for innate immunity activation), and TTX-siMYC (siRNA inhibitor of c-MYC). Additionally, R&D efforts are exploring the combination of TTX-MC138 and seviprotimut-L technologies to enhance therapeutic impact.
Transcode Therapeutics Inc 정보
종목 코드 RNAZ
회사 이름Transcode Therapeutics Inc
상장일Apr 28, 2021
CEOCalais (Philippe P)
직원 수7
유형Ordinary Share
회계 연도 종료Apr 28
주소6 Liberty Square
도시BOSTON
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02109
전화18573016857
웹사이트https://www.transcodetherapeutics.com/
종목 코드 RNAZ
상장일Apr 28, 2021
CEOCalais (Philippe P)
Transcode Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
+1.00%
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Thomas A. (Tom) Fitzgerald
Mr. Thomas A. (Tom) Fitzgerald
Chief Financial Officer, Vice President, Director
Chief Financial Officer, Vice President, Director
2.00
--
Dr. Philippe P. Calais, Ph.D.
Dr. Philippe P. Calais, Ph.D.
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
1.00
+1.00%
Dr. Erik Manting, Ph.D.
Dr. Erik Manting, Ph.D.
Independent Director
Independent Director
--
--
Dr. Magda Marquet, Ph.D.
Dr. Magda Marquet, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel Vlock
Dr. Daniel Vlock
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Elizabeth Czerepak
Ms. Elizabeth Czerepak
Independent Director
Independent Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Fri, Jan 9
마지막 업데이트: Fri, Jan 9
주주
주주 유형
주주
주주
비율
CK Life Sciences International Holdings, Inc.
9.08%
Sabby Management, LLC
4.54%
DRW Securities, LLC
1.28%
The Vanguard Group, Inc.
0.71%
Geode Capital Management, L.L.C.
0.58%
기타
83.82%
주주
주주
비율
CK Life Sciences International Holdings, Inc.
9.08%
Sabby Management, LLC
4.54%
DRW Securities, LLC
1.28%
The Vanguard Group, Inc.
0.71%
Geode Capital Management, L.L.C.
0.58%
기타
83.82%
주주 유형
주주
비율
Corporation
9.08%
Investment Advisor/Hedge Fund
5.11%
Investment Advisor
2.31%
Research Firm
0.28%
Individual Investor
0.14%
Hedge Fund
0.02%
기타
83.06%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
36
70.82K
7.72%
-29.38K
2025Q3
37
40.93K
4.61%
-48.04K
2025Q2
41
77.84K
18.97%
+69.48K
2025Q1
45
80.09K
9.69%
+74.47K
2024Q4
36
155.76K
22.37%
+143.23K
2024Q3
40
10.06K
1.97%
-8.53K
2024Q2
41
8.22K
4.45%
-5.03K
2024Q1
41
12.92K
7.67%
+11.92K
2023Q4
41
826.00
4.24%
+40.00
2023Q3
39
727.00
50.61%
+276.00
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
CK Life Sciences International Holdings, Inc.
83.28K
9.08%
+83.28K
--
Oct 27, 2025
Sabby Management, LLC
41.60K
4.54%
+41.60K
--
Dec 31, 2025
DRW Securities, LLC
11.70K
1.28%
+11.70K
--
Sep 30, 2025
The Vanguard Group, Inc.
6.54K
0.71%
--
--
Nov 30, 2025
Geode Capital Management, L.L.C.
4.93K
0.54%
--
--
Nov 30, 2025
Citi Investment Research (US)
1.59K
0.17%
+1.59K
--
Sep 30, 2025
Tracy (Thomas Joseph)
1.25K
0.14%
+1.25K
--
Mar 07, 2025
Desjardins Securities Inc.
975.00
0.11%
+975.00
--
Sep 30, 2025
Tower Research Capital LLC
142.00
0.02%
-260.00
-64.68%
Sep 30, 2025
더 보기
관련 ETF
이름
비율
데이터 없음
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
날짜
배당락일
유형
비율
Apr 16, 2025
Merger
28→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Nov 25, 2024
Merger
33→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
Jan 11, 2024
Merger
40→1
May 22, 2023
Merger
20→1
더 보기
